Dofferhoff A S, Bom V J, de Vries-Hospers H G, van Ingen J, vd Meer J, Hazenberg B P, Mulder P O, Weits J
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Crit Care Med. 1992 Feb;20(2):185-92. doi: 10.1097/00003246-199202000-00007.
To study the patterns of plasma concentrations of endotoxin, tumor necrosis factor-alpha (TNF), interleukin-6 (IL-6), plasminogen activator inhibitor-1, C-reactive protein, and serum amyloid A during the treatment of human sepsis.
A prospective case series study.
ICU of the Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Twenty consecutive patients (11 female, 9 male, mean age 67 yrs) with clinically defined sepsis. Eighteen patients were admitted from the outpatient emergency ward; two patients were already inpatients. The control group (n = 7) comprised patients with nonseptic shock.
Ten (50%) septic patients had detectable endotoxemia (greater than 5 (ng/L). TNF concentrations on admission were increased in 94% of the septic patients, whereas IL-6 and plasminogen activator inhibitor plasma concentrations were increased in all septic patients. The septic group showed significantly (p less than .05) higher concentrations of TNF, IL-6, plasminogen activator inhibitor-1, C-reactive protein, and serum amyloid A compared with the nonseptic patients. In the septic group, we found a correlation of both IL-6 and plasminogen activator inhibitor concentrations with severity of illness (r2 = .33, p less than .05; r2 = .22, p less than .05, respectively). After the start of antibiotic treatment, high concentrations of TNF and plasminogen activator inhibitor persisted in the nonsurvivors in contrast to decreasing concentrations in most of the survivors. After an initial increase in seven patients, IL-6 concentrations decreased in all septic patients and also in nonsurvivors.
This study confirms previous findings that: a) TNF is a major mediator involved in the pathogenesis of septic shock; b) plasminogen activator inhibitor activity is significantly increased in septic patients and might be involved in the pathogenesis of disseminated intravascular coagulation associated with sepsis; and c) IL-6 is involved in the pathophysiology of septic shock, although further studies are needed to determine whether IL-6 is directly involved in mediating the lethal complications of septic shock or whether it should be considered an "alarm hormone" that reflects endothelial cell injury. Our findings also suggest that the concentrations and trends of these mediators during treatment are valuable for monitoring septic patients.
研究人类脓毒症治疗期间血浆中内毒素、肿瘤坏死因子-α(TNF)、白细胞介素-6(IL-6)、纤溶酶原激活物抑制剂-1、C反应蛋白和血清淀粉样蛋白A的浓度变化模式。
前瞻性病例系列研究。
荷兰格罗宁根大学医院内科重症监护病房。
20例临床确诊为脓毒症的连续患者(11例女性,9例男性,平均年龄67岁)。18例患者来自门诊急诊病房;2例患者为住院患者。对照组(n = 7)包括非脓毒症休克患者。
10例(50%)脓毒症患者检测到内毒素血症(大于5(ng/L))。94%的脓毒症患者入院时TNF浓度升高,而所有脓毒症患者的IL-6和纤溶酶原激活物抑制剂血浆浓度均升高。与非脓毒症患者相比,脓毒症组的TNF、IL-6、纤溶酶原激活物抑制剂-1、C反应蛋白和血清淀粉样蛋白A浓度显著更高(p <.05)。在脓毒症组中,我们发现IL-6和纤溶酶原激活物抑制剂浓度均与疾病严重程度相关(r2 =.33,p <.05;r2 =.22,p <.05)。抗生素治疗开始后,非存活者中TNF和纤溶酶原激活物抑制剂持续保持高浓度,而大多数存活者中的浓度下降。7例患者IL-6浓度最初升高后,所有脓毒症患者及非存活者的IL-6浓度均下降。
本研究证实了先前的发现:a)TNF是脓毒症休克发病机制中的主要介质;b)脓毒症患者纤溶酶原激活物抑制剂活性显著增加,可能参与了与脓毒症相关的弥散性血管内凝血的发病机制;c)IL-6参与脓毒症休克的病理生理过程,尽管需要进一步研究以确定IL-6是否直接参与介导脓毒症休克的致命并发症,或者它是否应被视为反映内皮细胞损伤的“警报激素”。我们的研究结果还表明,这些介质在治疗期间的浓度和变化趋势对监测脓毒症患者具有重要价值。